Share
Regulation formalised a division the industry was already drawing. Since then, sales panels, search behaviour and brand portfolios have begun describing different slices of what used to look like one market.
***
ON 21 January 2026, Kenvue took an established brand and cut it in half. ORSL, the name it had spent years building, was reserved for a WHO-formula product for diarrhoeal dehydration, in powder and ready-to-drink formats. A second brand, eRZL, was created for everyday hydration and positioned against heat exhaustion, muscle cramps and tiredness.
The new architecture maps almost exactly on to the line the regulator had drawn. Three months earlier, on 14 October 2025, FSSAI withdrew every permission that had allowed food-licensed products to carry the term "ORS" in their branding. The Delhi High Court declined to interdict the orders in a judgment of 3 November, and a national enforcement directive to states followed later that month. Genuine ORS, regulated as a drug and required to meet the WHO formulation, keeps the term. Food products that had used the term had to find new names.
What has happened since is that three visible signals from this market have started describing different things.
The panel says the category is contracting
PharmaTrac, which audits pharmaceutical sales through a stockist panel, shows the ORS market shrinking. March 2026 sales fell to ₹85 crore from ₹115 crore a year earlier, a decline of 26 per cent, with moving annual turnover down 8 per cent to ₹1,128 crore. Electral, the FDC brand that has long led the category, saw MAT value fall 7 per cent.
The tempting reading is that the ban did this. PharmaTrac is more careful, noting the fall has to be read against a high base and normal seasonal patterns. FDC's own FY26 results support that caution. Domestic formulations grew 0.1 per cent across the year and 8.5 per cent in the fourth quarter, with the company attributing the muted annual figure to "subdued performance in top brands like Zifi, Electral and Enerzal". Zifi is an antibiotic. Whatever is happening to Electral is happening alongside something broader than a labelling rule.
Search favours "ORS" and "electrolyte" over "hydration"
Indian search behaviour, measured across a window that is predominantly post-ban, still runs heavily on clinical and functional language. "ORS powder" draws an estimated 74,000 average monthly searches, ahead of "electrolyte powder" at 60,500. The industry's preferred lifestyle vocabulary is far smaller: "electrolyte powder" outdraws "hydration powder" by roughly 46 times, and "electrolyte drink" outdraws "hydration drink" by about 14.
This establishes what language is salient. It does not establish what anyone bought, and it does not demonstrate continuity from before the ban. A large share of those ORS searches may be people looking for precisely what the regulation protects: a therapeutic product still entitled to the name.
One pattern is worth noting without treating it as a trend. In powder queries, "ORS" leads "electrolyte" by about 1.2 to one; among drink queries, the two sit in the same SEMrush volume bucket. That may indicate functional language has travelled further in the drink format, but without historical or behavioural data it remains a hypothesis.
The brands were already moving
The everyday-hydration push did not begin in October 2025. Cipla was describing the entire beverage industry as Prolyte's addressable market in November 2024. Reliance entered the category with RasKik Gluco Energy at ₹10 in January 2025, and HUL brought Liquid I.V. to India that April, positioned around exercise, heat, travel and active lifestyles.
FSSAI did not create this shift. It formalised a distinction the industry was already drawing, and converted it from a marketing choice into a labelling requirement.
Why the three layers do not meet
These signals should not be forced into one chart. PharmaTrac's ORS series is built from pharmaceutical stockist sales; search volume records queries rather than purchases; and products such as eRZL, RasKik and Liquid I.V. sit across food, wellness and retail channels. Publicly available methodology does not show how renamed electrolyte foods are classified within the ORS series, or what proportion of their sales it captures.
That makes reclassification and channel movement plausible explanations for part of the recorded decline, alongside a high base, seasonality and genuine demand loss. The figures cannot apportion the fall among them.
The practical problem arises when the ORS number is used as shorthand for the wider hydration opportunity: it now describes a narrower, medically defined slice at exactly the moment the broader category is being rebuilt.
Renaming also creates a less visible commercial task. eRZL inherits Kenvue's distribution and visibly echoes ORSL, but the company cannot assume that the old name's search behaviour will transfer. The most promising generic bridge may be "electrolyte", which already attracts substantial search, rather than the much smaller word "hydration". Rebuilding discoverability is a strategic risk; this dataset cannot yet price it.
Each signal answers a different question. The commercial error would be to treat any one of them as the market.
THE NUMBERS
74,000 | Estimated average monthly Indian searches for "ORS powder", the largest of the nine category terms examined |
60,500 | The same measure for "electrolyte powder" |
46x | How far "electrolyte powder" outdraws "hydration powder" |
14x | How far "electrolyte drink" outdraws "hydration drink". Generic "hydration" vocabulary remains much smaller in search |
−26% | Year-on-year fall in ORS sales value, March 2026, per PharmaTrac. Read against a high base and normal seasonality |
₹1,128 cr | ORS market moving annual turnover after an 8 per cent decline |
−7% | Electral's MAT value decline, despite being the compliant category leader |
Method: Search volumes are SEMrush India, database updated August 2026, estimated average monthly volume over the preceding twelve months, a window that is predominantly but not entirely post-ban. Volumes are estimates of queries, not of people, purchases or sales. Overlapping terms have not been summed, and the nine terms examined are not an exhaustive map of the category. Sales figures are PharmaTrac as reported by the Economic Times, and FDC's audited FY26 results.
WHY THIS MATTERS FOR BRANDS
1. Do not use ORS data as a proxy for the entire hydration opportunity.
First establish which products and channels the series captures before treating contraction as lost consumer demand.
2. "Electrolyte" is the available bridge language.
Generic searches using "hydration" remain far smaller; brands should not rely on lifestyle vocabulary alone.
3. Treat renaming as a brand-building investment.
Do not assume a successor name inherits its predecessor's search equity; measure branded search, referral traffic and repeat purchase before attempting to price the loss.
